Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at
increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

BACKGROUND: Cytochrome P450 (CYP) 2C19 plays a key role in clopidogrel activation
and thus impacts the clinical outcome of patients with coronary artery disease (CAD) …

Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

With clopidogrel treatment after acute coronary syndrome or percutaneous coronary
intervention (PCI), or both, the presence of any loss-of-function cytochrome P450 2C19 …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been
hypothesized to be associated with lesser degrees of platelet inhibition and increased risk …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …